Biocon biologics completes acquisition of viatris' global biosimilars business

Completes the multi-billion-dollar, cash & stock deal creates a unique, fully integrated, leading global biosimilars enterprise with eight commercialized products biocon biologics will recognize the combined revenue & associated profits from the acquired collaboration biosimilars with immediate effect viatris to provide commercial and other services for up to 2 years to ensure a seamless transition and continued service to patients and customers bengaluru, india , nov. 29, 2022 /prnewswire/ --  biocon biologics ltd. , a subsidiary of biocon ltd.
VTRS Ratings Summary
VTRS Quant Ranking